Merus N.V.
(NASDAQ:MRUS)
$24.21
0.07 (0.29%)
At Close: 4:00PM
MRUS Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
MRUS Stock Price Today
Merus N.V. (MRUS) stock rallied over 0.29% intraday to trade at $24.21 a share on NASDAQ. The stock opened with a loss of -15.04% at $20.51 and touched an intraday high of $20.85, rising 0.29% against the last close of $24.14. The Merus N.V. in stock market went to a low of $19.95 during the session.
MRUS Stock Snapshot
$24.14
Prev. Close
1.4 Billion
Market Cap
$19.95
Day Low
$20.51
Open
N/A
Number of Shares
$20.85
Day High
N/A
P/E ratio
-3.72
EPS (TTM)
6.73
Cash Flow per Share
N/A
Free Float in %
6.81
Book Value
609112.00
Volume
MRUS Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta0.81
Sales or Revenue$45.67 Million
5Y Sales Change17.41%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Peers
Frequently Asked Questions
What is the current Merus N.V. (MRUS) stock price?
Merus N.V. (NASDAQ: MRUS) stock price is $24.21 in the last trading session. During the trading session, MRUS stock reached the peak price of $20.85 while $19.95 was the lowest point it dropped to. The percentage change in MRUS stock occurred in the recent session was 0.29% while the dollar amount for the price change in MRUS stock was $0.07.
MRUS's industry and sector of operation?
The NASDAQ listed MRUS is part of Biotechnology industry that operates in the broader Healthcare sector. Merus N. V.
Who are the executives of MRUS?
Dr. Sven Ante Lundberg M.D.
Chief Executive Officer, Pres, Principal Financial Officer & Executive Director
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Senior Vice President
Dr. Hui Liu Ph.D.
Chief Bus. Officer, Executive Vice President & Head of Merus U.S.
Mr. Alexander Berthold Hendrik Bakker Ph.D.
Chief Devel. Officer & Executive Vice President
How MRUS did perform over past 52-week?
MRUS's closing price is 0.56% higher than its 52-week low of $12.03 where as its distance from 52-week high of $27.7 is -0.39%.
How many employees does MRUS have?
Number of MRUS employees currently stands at N/A. MRUS operates from Yalelaan 62, Utrecht, 3584 CM, NL.
Link for MRUS official website?
Official Website of MRUS is: https://www.merus.nl
How do I contact MRUS?
MRUS could be contacted at phone #31 30 253 8800 and can also be accessed through its website. MRUS operates from Yalelaan 62, Utrecht, 3584 CM, NL.
How many shares of MRUS are traded daily?
MRUS stock volume for the day was 609112.00 shares. The average number of MRUS shares traded daily for last 3 months was 339.6 Thousands.
What is the market cap of MRUS currently?
The market value of MRUS currently stands at $1.4 Billion with its latest stock price at $24.21 and N/A of its shares outstanding.